Updated 0 sec ago

Stocks

NamePrice24h ChangeMarket Cap24h High / Low7d Change
S&P 500$7,700.39▼ -0.24%—H 7,705 / L 7,670▼ -1.42%
Nasdaq 100$29,605.76▼ -1.15%—H 29,655 / L 29,408▼ -4.14%
Dow Jones$51,881.23▲ 0.50%—H 51,931 / L 51,681▲ 0.44%
AAPL$345.13▲ 0.63%$5.04TH 347.85 / L 344.30▲ 2.52%
MSFT$533.50▼ -0.04%$3.96TH 539.32 / L 531.22▼ -0.29%

US market data via Stooq · Yahoo Finance · Nasdaq · USD

Crypto

NamePrice24h ChangeMarket Cap24h High / Low7d Change
BTC Bitcoin$81,091.00▼ -1.00%$1.63TH 82,011 / L 79,806▼ -2.57%
ETH Ethereum$2,368.46▼ -2.51%$289.40BH 2,451 / L 2,325▼ -7.54%
XRP$1.3100▼ -2.11%$82.68BH 1.3400 / L 1.2900▼ -7.71%
SOL Solana$102.97▼ -1.08%$60.71BH 105.22 / L 100.99▼ -9.77%
DOGE Dogecoin$0.0785▼ -4.05%$12.29BH 0.0831 / L 0.0782▼ -9.35%

Live prices via CoinGecko · USD

Zymeworks completes Theravance acquisition

  • This topic has 0 replies, 1 voice, and was last updated 3 weeks ago by Master 👑 Lv.100 Master.
Viewing 1 post (of 1 total)
  • Author
    Posts
  • #343
    Master
    Keymaster
    👑 Lv.100 Master

    The deal combines royalty assets and R&D pipelines. A final transaction briefing was scheduled for September 28.

    Market impact: It signals continued mid-cap biotech M&A and royalty aggregation.

    Source: GlobeNewswire · Caution · Section: Health, Macro & Commodities

Viewing 1 post (of 1 total)

Join Bull Lounge to participate — Log in / Register

Today's visitors 34 · Online 0
Scroll to Top